Analysis of CDKN1A polymorphisms: markers of cancer susceptibility?

Página do item simplificado
dc.contributor.authorRodrigues, FCC
dc.contributor.authorKawasaki-Oyama, R. S.
dc.contributor.authorFo, JFG
dc.contributor.authorUkuyama, E. E.
dc.contributor.authorAntonio, JR
dc.contributor.authorBozola, A. R.
dc.contributor.authorRomeiro, J. G.
dc.contributor.authorRahal, Paula [UNESP]
dc.contributor.authorTajara, E. H.
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionFaculdade de Medicina de Marília (FAMEMA)
dc.contributor.institutionHosp Arnaldo Vieira de Carvalho
dc.contributor.institutionFac Med
dc.date.accessioned2014-05-20T15:25:34Z
dc.date.available2014-05-20T15:25:34Z
dc.date.issued2003-04-15
dc.description.abstractThe CDKN1A (TP21)(2) gene encodes a 21-kD protein that is a critical downstream mediator of wild-type TP53 and an important regulator of the cell cycle. Failure in the function of this gene would be expected to result in abnormal cell proliferation and transformation. Tumor-associated mutations of the coding region of the TP21 are rare. on the other hand, some TP21 polymorphisms have been identified and characterized by single base substitutions. In the present study, we investigated the potential role of TP21 gene polymorphisms in skin, head, and neck tumorigenesis. A total of 261 samples were examined by polymerase chain reaction single-strand conformational analysis, and one mutation at codon 31 and four polymorphisms in exons 2 (codon 55) and 3 [nucleotide (nt)590] and in promoter region (nt2298) were identified. In conclusion, this investigation confirmed the rarity of mutations in this gene, arguing against a role for TP21 mutations in skin, head, and neck cancers. Also, our results show significant differences in nt2298 allele frequencies between normal individuals and skin malignant tumors (P < 0.05). The results suggest that this polymorphism affects TP21 transactivator binding and may be important during the pathogenesis of skin cancer. (C) 2003 Elsevier B.V. All rights reserved.en
dc.description.affiliationUniv Estadual Paulista, Dept Biol, Sao Carlos do Rio Preto, SP, Brazil
dc.description.affiliationFac Med Marilia, Hemoctr, São Paulo, Brazil
dc.description.affiliationHosp Arnaldo Vieira de Carvalho, São Paulo, Brazil
dc.description.affiliationFac Med, Serv Dermatol, Sao Carlos do Rio Preto, SP, Brazil
dc.description.affiliationUnespUniv Estadual Paulista, Dept Biol, Sao Carlos do Rio Preto, SP, Brazil
dc.format.extent92-98
dc.identifierhttp://dx.doi.org/10.1016/S0165-4608(02)00839-7
dc.identifier.citationCancer Genetics and Cytogenetics. New York: Elsevier B.V., v. 142, n. 2, p. 92-98, 2003.
dc.identifier.doi10.1016/S0165-4608(02)00839-7
dc.identifier.issn0165-4608
dc.identifier.lattes7991082362671212
dc.identifier.orcid0000-0001-5693-6148
dc.identifier.urihttp://hdl.handle.net/11449/35951
dc.identifier.wosWOS:000182381100002
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.ispartofCancer Genetics and Cytogenetics
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.titleAnalysis of CDKN1A polymorphisms: markers of cancer susceptibility?en
dc.typeArtigo
dcterms.licensehttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dcterms.rightsHolderElsevier B.V.
unesp.author.lattes7991082362671212[8]
unesp.author.orcid0000-0003-4235-0925[2]
unesp.author.orcid0000-0002-8855-9049[1]
unesp.author.orcid0000-0002-2603-2057[9]
unesp.author.orcid0000-0001-5693-6148[8]
unesp.campusUniversidade Estadual Paulista (Unesp), Instituto de Biociências Letras e Ciências Exatas, São José do Rio Pretopt

Arquivos

Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:

Coleções

Artigos - Biologia - IBILCE